Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC)

Lung, Respiratory and Thoracic Cancer

Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

J Thorac Oncol

Said BI, Geng Y, Badiyan SN, Bang A, Bezjak A, Chua KLM, Faivre-Finn C, Kong FM, Przybysz D, Putora PM, Munoz-Schuffenegger P, Siva S, Xu-Welliver M, McDonald F, Louie A, Chun SG

doi: 10.1016/j.jtho.2024.09.1437

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

★ 2 Recommended by Dr Wolf-Dieter Janthur, Faculty Member

Lancet

Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S, KEYNOTE-671 Investigators

doi: 10.1016/S0140-6736(24)01756-2

Lung, Respiratory and Thoracic Cancer

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor (R) Classification for Lung Cancer. Results from an International Survey among Pathologists and Thoracic Surgeons

J Thorac Oncol

Hoffmann H, Nicholson AG, Detterbeck FC, Tsao MS, Ostrowski M, Rami-Porta R, Borczuk A, Marino M, Travis WD, Van Schil PE, Edwards J, Members of the R-Subcommittee, and Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards

doi: 10.1016/j.jtho.2024.12.007

Lung, Respiratory and Thoracic Cancer

The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study

Lung Cancer

de Ruiter JC, van der Noort V, van Diessen JNA, Smit EF, Damhuis RAM, Hartemink KJ, ESLUNG group

doi: 10.1016/j.lungcan.2024.107792

Lung, Respiratory and Thoracic Cancer

Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis

Cancers (Basel)

Girard N, Besada M, Rogula B, Lucherini S, Vo L, Chaudhary MA, Goring S, Lozano-Ortega G, Tran M, Varol N, Waser N, Lee JM, Spicer J

doi: 10.3390/cancers16132492

Lung, Respiratory and Thoracic Cancer

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective

Lung Cancer

Grit GF, van Geffen E, Malmberg R, van Leeuwen R, Böhringer S, Jm Smit H, Brocken P, Fh Eijsink J, Dronkers E, Gal P, Jaarsma E, Jhm van Drie-Pierik R, Mp Eldering-Heldens A, Machteld Wymenga AN, Gm Mol P, Zwaveling J, Hilarius D

doi: 10.1016/j.lungcan.2024.107950

Lung, Respiratory and Thoracic Cancer

Tumour spread through air spaces is a determiner for treatment of clinical stage I non-small cell lung Cancer: Thoracoscopic segmentectomy vs lobectomy

Lung Cancer

Huang L, Petersen RH

doi: 10.1016/j.lungcan.2025.108438

Lung, Respiratory and Thoracic Cancer

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

Lung Cancer

Tambo Y, Sone T, Nishi K, Shibata K, Kita T, Araya T, Shirasaki H, Shimizu T, Yoneda T, Matsuoka H, Nanjo S, Koba H, Terada N, Ueda T, Nomura S, Murase Y, Yano S

doi: 10.1016/j.lungcan.2025.108422

Lung, Respiratory and Thoracic Cancer

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study

Lung Cancer

Pons-Tostivint E, Ezzedine R, Goronflot T, Crequit P, Chatellier T, Raimbourg J, Bennouna J, Giroux Leprieur E, Porte M

doi: 10.1016/j.lungcan.2024.107887

Related content

Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor (R) Classification for Lung Cancer. Results from an International Survey among Pathologists and Thoracic Surgeons

The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study

Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective

Tumour spread through air spaces is a determiner for treatment of clinical stage I non-small cell lung Cancer: Thoracoscopic segmentectomy vs lobectomy

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study